Serum β2—Microglobulin Levels in Patients with Various Solid Cancer

Abstract

Background: The level of β2-M has become one of the most important prognostic factors and predictors of survival in patients with certain caner. The aim of this study was to investigate the serum levels of β2-M in patients with various solid cancers, to find the prognostic and predictive value of serum β2-M level elevating in patients with solid cancer. Methods: A total of 1158 serum from 774 patients with various solid cancer and 384 patients with various solid benign tumor patients were analyzed by β2-microglobulin ELISA kit, the data were analyzed by using statistical 36 packages for sciences (spss11.0) software. Results: In patients with thyroid cancer, patients with breast cancer and that with liver cancer the mean β2-microglobulin levels and positive rate were significantly higher than that in controls (p 0.05), and the positive rats were not significantly different compared with that in controls (p>0.05) except the patients with esophagus cancer in which the positive rate was significantly different compared with that in controls (p < 0.01). In female breast cancer patients the mean β2- microglobulin levels and the positive rate were significantly higher than that in breast benign tumor patients (p<0.05: p<0.05), no significant difference stages and clinical stages. In thyroid cancer patients the mean β2-microglobulin levels and the positive rate were significantly higher than that in thyroid benign tumor patients (p< 0.05, p< 0.01), no significant difference in sex, ages, clinical stages, but the mean β2-microglobulin levels and the positive rate were significantly higher in patients with follicular thyroid cancer than that in patients with mamillary thyroid 54 cancer patients. Conclusion: β2-M is an important tumor marker in breast, thyroid and liver cancer that would be one of assistantly diagnostic factors in patients with these cancers.